Neuroscientific Biopharmaceuticals Ltd. · ASX:NSB
Neuroscientific Biopharmaceuticals — AusBiotech 2025
12 slides from Neuroscientific Biopharmaceuticals's conference presentation, Oct 21, 2025
Slide 1: Patented Stem Cell Solutions for Complex Auto-Immune Disorders & Unmet Needs
ASX: NSB Patented Stem Cell Solutions for Complex Auto-Immune Disorders & Unmet Needs For personal use only Nathan Smith | Chief Executive Officer 01 02 03 04 Robust Profile & StemSmart Proven Secure Strong Balance Sheet Tech Platform Clinical Efficacy Supply Chain ~$50M market cap Method of manufac
Slide 2: Strength in Leadership & Advisory
Strength in Leadership & Advisory ROB MCKENZIE DR ANTON UVAROV LL.B; B.Juris, FAICD PhD, MBA NON-EXECUTIVE CHAIRMAN NON-EXECUTIVE DIRECTOR • Lawyer with over 35 years’ experience in corporate and commercial • Significant healthcare industry experience with a focus on neuroscience transactions, restr
Slide 3: Introducing StemSmart
Introducing StemSmart The StemSmart MSC product is potent, efficacious and safe1 US FDA Approval of MSCs StemSmart is a global patented technology For personal use only Pathway to Commercialisation in US resulting in differentiated MSC from others in product class The United States FDA’s recent appr
Slide 4: Stem Cell Technology for Refractory Crohn's
Stem Cell Technology for Refractory Crohn’s Refractory Crohn’s (Life-Threatening) Special Access Program (Commenced June 2025) • Unresponsive to conventional therapies Crohn’s Fistulas (Antibiotics/Steroids/Biologics) Treat patients with Crohn’s Fistulas on compassionate grounds For personal use onl
Slide 5: Key Milestones
Key Milestones Crohn’s Disease - StemSmart 2026 2027 2028 2029 2030 SAS Program – Fistulising Crohn’s Disease (Commenced June 2025) Phase 2 Start-up Activities For personal use only Phase 2 Phase 2 Trial (Australia & US) Results Partnership Finalisation Phase 3 Start-up Activities Phase 3 Phase 3 Tr
Slide 6: Product Pipeline & Market Size
Product Pipeline & Market Size Key Clinical Targets (StemSmartTM Addressable Markets) Forecast Global Market Increase in Market • Need for more effective treatments with less side effects US$13.8 billion Crohn’s Disease • Require additional treatment option for patients who have failed all By 2026 1
Slide 7: Securing the StemSmart Supply Chain
Securing the StemSmart Supply Chain Partnership with Q-Gen Cell Therapeutics1 Tech transfer has been initiated for NSB’s patented manufacturing process with targeting Phase 2 clinical trial supply by 2H CY 2026. For personal use only Q-Gen has a 13-cleanroom facility that has been licensed by the TG
Slide 8: The Vision for Stem Cell Therapies
The Vision for Stem Cell Therapies… Global Crohn’s Solution for Over 6 Million people are living with Crohn’s globally (over 1 million in US alone) with Unmet Medical Need over 30% not responding to conventional treatment including blockbuster biologics. Patented Platform For personal use only Signi
Slide 9: Audience Q&A
ASX NSB For personal use only Audience Q&A Nathan Smith Dr Anton Uvarov Chief Executive Officer Founding Non-Executive Director +61 477 738 404 +61 8 6268 2641 nsmith@neuroscientific.com au@neuroscientific.com 9
Slide 10: Appendix
For personal use only Appendix ASX NSB 10
Slide 11: Company Overview
Company Overview Corporate Share Information Capital Structure & Cash On Hand As at 10 October 2025 ORDINARY SHARES PERFORMANCE SHARES OPTIONS SHARE PRICE A$0.15 CAPITAL 333.2 million 57.1 million 45.25 million For personal use only MARKET CAPITALISATION ~A$49.89 million CASH ~$7.3 million Share Pri
Slide 12: Disclaimers
Disclaimers Presentation Information Forward Looking Statements This presentation has been prepared by NeuroScientific Biopharmaceuticals Ltd (ASX : This presentation contains certain forward -looking statements that are based on the NSB) based on information available to it as at the date of this p